|
Subsequent Events (Details Textual)
|
0 Months Ended | 1 Months Ended | 12 Months Ended | 78 Months Ended | 2 Months Ended | 1 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 27, 2012
USD ($)
|
Feb. 28, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2012
USD ($)
|
Mar. 08, 2013
Subsequent Event [Member]
USD ($)
|
Feb. 22, 2013
Subsequent Event [Member]
|
Feb. 28, 2013
Subsequent Event [Member]
Research and Development Arrangement [Member]
USD ($)
|
Feb. 28, 2013
Subsequent Event [Member]
Research and Development Arrangement [Member]
EUR (€)
|
Feb. 22, 2013
Subsequent Event [Member]
Joint Ownership and Exclusive License Agreement FU Berlin [Member]
USD ($)
|
Feb. 22, 2013
Subsequent Event [Member]
Joint Ownership and Exclusive License Agreement FU Berlin [Member]
EUR (€)
|
Feb. 22, 2013
Subsequent Event [Member]
Joint Ownership and Exclusive License Agreement FU Berlin [Member]
Maximum [Member]
|
Feb. 22, 2013
Subsequent Event [Member]
Joint Ownership and Exclusive License Agreement FU Berlin [Member]
Minimum [Member]
|
Feb. 22, 2013
Subsequent Event [Member]
License and Sublicense Agreement with Ovamed GmbH [Member]
USD ($)
|
Feb. 22, 2013
Subsequent Event [Member]
License and Sublicense Agreement with Ovamed GmbH [Member]
EUR (€)
|
Feb. 22, 2013
Subsequent Event [Member]
License and Sublicense Agreement with Ovamed GmbH [Member]
Maximum [Member]
|
Feb. 22, 2013
Subsequent Event [Member]
License and Sublicense Agreement with Ovamed GmbH [Member]
Minimum [Member]
|
|
| Subsequent Event (Textual) [Abstract] | |||||||||||||||||||
| Expected project duration under Research Agreement | 4 years | 4 years | |||||||||||||||||
| Research fees paid to FU Berlin | $ 17,468,000 | $ 8,583,000 | $ 8,341,000 | $ 42,009,000 | $ 843,000 | € 648,000 | |||||||||||||
| Written notice period under Research Agreement Termination | 3 months | 3 months | |||||||||||||||||
| Potential milestone payments based primarily on the achievement of clinical development and regulatory milestones | 4,982,000 | 3,830,000 | |||||||||||||||||
| Percentage of royalty on net sales of products range | 2.50% | 1.00% | 2.50% | 1.00% | |||||||||||||||
| Maximum potential payment based on achievement of regulatory milestones, | 1,333,000 | 1,025,000 | |||||||||||||||||
| Right Interest in Joint Intellectual Property | 10.00% | ||||||||||||||||||
| Issuance of Common stock to founders, shares | 5,750,000 | 3,361 | 1,426,250 | ||||||||||||||||
| Net proceeds from public offering of Common Stock | $ 26,400,000 | $ 28,855,000 | $ 193,000 | $ 29,053,000 | $ 10,500,000 | ||||||||||||||
| Notice period to cure termination due to breach | 60 days | ||||||||||||||||||
| Period of notice for termination of Joint Ownership and exclusive license agreement | 60 days | ||||||||||||||||||
| Period of Written notice for termination of Joint Ownership and exclusive license agreement | 180 days | ||||||||||||||||||